Second-line ARV access increased through Clinton, Pfizer and Mylan agreement
This article was originally published in Scrip
Executive Summary
The prices of second-line treatments for HIV and tuberculosis in the developing world have been cut after an agreement was signed between the Clinton Foundation's HIV/AIDS Initiative (CHAI), Pfizerand Mylan.